-
Product Insights
NewLikelihood of Approval Analysis for Hypoglycemia
Overview How likely is it that the drugs in Hypoglycemia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hypoglycemia Overview Hypoglycemia is a condition characterized by an abnormally low level of...
-
Product Insights
NewLikelihood of Approval Analysis for Major Depressive Disorder
Overview How likely is it that the drugs in Major Depressive Disorder will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Major Depressive Disorder Overview Major Depressive Disorder (MDD) is a common...
-
Product Insights
NewLikelihood of Approval Analysis for Relapsed Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that the drugs in Relapsed Chronic Lymphocytic Leukemia (CLL) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relapsed Chronic Lymphocytic Leukemia (CLL) Overview Relapsed Chronic Lymphocytic...
-
Product Insights
NewLikelihood of Approval Analysis for Bipolar I Disorder
Overview How likely is it that the drugs in Bipolar I Disorder will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bipolar I Disorder Overview Bipolar I Disorder is a mental health...
-
Product Insights
NewLikelihood of Approval Analysis for Traumatic Pain
Overview How likely is it that the drugs in Traumatic Pain will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Traumatic Pain Overview Traumatic pain arises from physical injuries or trauma to...
-
Product Insights
NewLikelihood of Approval Analysis for Rhinosinusitis
Overview How likely is it that the drugs in Rhinosinusitis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhinosinusitis Overview Rhinosinusitis is a condition that affects the nasal and sinus mucosa,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocrelizumab in Autoimmune Encephalitis (Post-Infectious)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocrelizumab in Autoimmune Encephalitis (Post-Infectious) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocrelizumab in Autoimmune Encephalitis (Post-Infectious) Drug Details: Ocrelizumab (Ocrevus) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...
-
Sector Analysis
NewMexico Upstream (Oil and Gas) Fiscal and Regulatory Guide, 2024
Mexico Upstream Fiscal and Regulatory Report Overview The upstream fiscal and regulatory outlook of Mexico has undergone many changes. Mexico has implemented different regimes for oil exploration and production, including Production Sharing Agreements (PSAs), Concession Agreements, Service Contracts, and PEMEX's Entitlement Regime. Private development of fields has been halted since 2018, when President Lopez Obrador put a stop to Licensing Rounds in a bid to position PEMEX as the sole player in upstream development, with the company already securing a...
-
Sector Analysis
NewBusiness of the Formula One 2024 – Property Profile, Sponsorship and Media Landscape
Reasons to buy the ‘Business of the Formula One’ report: In-depth analysis of sponsorship and media revenue generated for the 2023-24 season. Detailed team analysis by breaking down the main commercial deals around each of the 30 competing teams from both a sponsorship and media perspective. A comprehensive overview and expert insight of the league that is well regarded as the pinnacle of motor racing anywhere in the world. How is our ‘Business of the Formula One’ report unique from...